Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
February 22 2021 - 7:30AM
Business Wire
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with open-angle glaucoma, ocular surface diseases and
retinal diseases, today announced that the Company will participate
in the following virtual investor conferences.
- 10th Annual SVB Leerink Global Healthcare Conference
- Date: Friday, February 26, 2021
- Time: 2:20 p.m. Eastern Time
- Presenter: Richard J. Rubino, Chief Financial Officer
- Presentation Type: Fireside
- 41st Annual Cowen Healthcare Conference
- Date: Tuesday, March 2, 2021
- Time: 9:50 a.m. Eastern Time
- Presenter: Vicente Anido, Jr., Ph.D., Chairman and Chief
Executive Officer
- Presentation Type: Fireside
- Raymond James & Associates’ 42nd Annual Institutional
Investors Conference
- Date: Wednesday, March 3, 2021
- Time: 11:40 a.m. Eastern Time
- Presenter: Richard J. Rubino, Chief Financial Officer
- Presentation Type: Fireside
The fireside discussions will be webcast live and may be
accessed by visiting Aerie’s website at
http://investors.aeriepharma.com. A replay of each fireside
discussion will be available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with open-angle glaucoma,
ocular surface diseases and retinal diseases. Aerie’s first
product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a
once-daily eye drop approved by the U.S. Food and Drug
Administration (FDA) for the reduction of elevated intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension, was launched in the United States in April 2018. In
clinical trials of Rhopressa®, the most common adverse reactions
were conjunctival hyperemia, corneal verticillata, instillation
site pain, and conjunctival hemorrhage. More information about
Rhopressa®, including the product label, is available at
www.rhopressa.com. Aerie’s second product for the reduction of
elevated IOP in patients with open-angle glaucoma or ocular
hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic
solution) 0.02%/0.005%, the first and only fixed-dose combination
of Rhopressa® and the widely-prescribed PGA (prostaglandin analog)
latanoprost, was launched in the United States in May 2019. In
clinical trials of Rocklatan®, the most common adverse reactions
were conjunctival hyperemia, corneal verticillata, instillation
site pain, and conjunctival hemorrhage. More information about
Rocklatan®, including the product label, is available at
www.rocklatan.com. Aerie continues to focus on global expansion and
the development of additional product candidates and technologies
in ophthalmology, including for wet age-related macular
degeneration and diabetic macular edema. More information is
available at www.aeriepharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210222005011/en/
Media: Tad Heitmann 949-526-8747; theitmann@aeriepharma.com
Investors: Ami Bavishi 908-947-3949; abavishi@aeriepharma.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Sep 2023 to Sep 2024